Safety study of SCR-6920 for advanced cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor, or certain NHL (lymphoma) that has come back or did not respond
- Your cancer has grown during standard treatment or standard treatment isn’t possible for you
- You have at least one measurable or evaluable tumor spot the study team can track
- Your overall health is fairly strong (ECOG 0–1) and you’re expected to live at least 12 weeks
- Your major organs (like liver, kidneys, and blood counts) are working well enough for study treatment
- You meet the study’s pregnancy/birth control rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SB-4826, for people with advanced solid tumors or certain types of lymphoma that have not responded to standard treatments. The goal is to see if the drug is safe and effective, either alone or with another drug called rituximab.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.